Impact of rituximab on immunoglobulin concentrations and B cell numbers after cyclophosphamide treatment in patients with ANCA-associated vasculitides

PLoS ONE

Volumn 7, Issue 5, 2012, Pages

  Venhoff, Nils ^a   Effelsberg, Nora M ^a   Salzer, Ulrich ^a   Warnatz, Klaus ^a   Peter, Hans Hartmut ^a   Lebrecht, Dirk ^a   Schlesier, Michael ^a   Voll, Reinhard E ^a   Thiel, Jens ^a  

^a UNIVERSITY OF FREIBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; IMMUNOGLOBULIN; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; LEFLUNOMIDE; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; RITUXIMAB; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

ADULT; AGED; ANCA ASSOCIATED VASCULITIS; ARTICLE; B LYMPHOCYTE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; HUMAN; HUMORAL IMMUNE DEFICIENCY; IMMUNOGLOBULIN DEFICIENCY; LYMPHOCYTE COUNT; MALE; POPULATION DYNAMICS; RESPIRATORY TRACT INFECTION; RETROSPECTIVE STUDY;

ADULT; AGED; ANTI-NEUTROPHIL CYTOPLASMIC ANTIBODY-ASSOCIATED VASCULITIS; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; B-LYMPHOCYTES; CYCLOPHOSPHAMIDE; FEMALE; HUMANS; IMMUNOGLOBULINS; IMMUNOLOGIC FACTORS; LYMPHOCYTE COUNT; MALE; MIDDLE AGED;

EID: 84861318148     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0037626     Document Type: Article

References (30)

1. Fauci AS, Wolff SM, Johnson JS, (1971) Effect of cyclophosphamide upon the immune response in Wegener's granulomatosis. N Engl J Med 285: 1493-1496.
2. Kallenberg CGM, Heeringa P, Stegeman CA, (2006) Mechanisms of Disease: pathogenesis and treatment of ANCA-associated vasculitides. Nat Clin Pract Rheumatol 2: 661-670.
3. Kallenberg CGM, (2011) Pathogenesis of ANCA-Associated Vasculitis, an Update. Clin Rev Allerg Immu 41: 224-231.
4. Krumbholz M, Specks U, Wick M, Kalled SL, Jenne D, et al. (2005) BAFF is elevated in serum of patients with Wegener's granulomatosis. Journal of Autoimmunity 25: 298-302.
5. Guerry M-JCJ, Brogan P, Bruce IN, D'Cruz DP, Harper L, et al. (2012) Recommendations for the use of rituximab in anti-neutrophil cytoplasm antibody-associated vasculitis. Rheumatology (Oxford) 51: 634-643.
6. Jones RB, Tervaert JWC, Hauser T, Luqmani R, Morgan MD, et al. (2010) Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis. N Engl J Med 363: 211-220.
7. Stone JH, Merkel PA, Spiera R, Seo P, Langford CA, et al. (2010) Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med 363: 221-232.
8. Gottenberg J-E, Ravaud P, Bardin T, Cacoub P, Cantagrel A, et al. (2010) Risk factors for severe infections in patients with rheumatoid arthritis treated with rituximab in the autoimmunity and rituximab registry. Arthritis Rheum 62: 2625-2632.
9. Stegeman CA, Tervaert JW, Sluiter WJ, Manson WL, de Jong PE, et al. (1994) Association of chronic nasal carriage of Staphylococcus aureus and higher relapse rates in Wegener granulomatosis. Ann Intern Med 120: 12-17.
10. Popa ER, Stegeman CA, Kallenberg CGM, Tervaert JWC, (2002) Staphylococcus aureus and Wegener's granulomatosis. Arthritis Res 4: 77-79.
11. Hunder GG, Arend WP, Bloch DA, Calabrese LH, Fauci AS, et al. (1990) The American College of Rheumatology 1990 criteria for the classification of vasculitis. Introduction. Arthritis Rheum 33: 1065-1067.
12. Masi AT, Hunder GG, Lie JT, Michel BA, Bloch DA, et al. (2010) The American College of Rheumatology 1990 criteria for the classification of churg-strauss syndrome (allergic granulomatosis and angiitis). Arthritis Rheum 33: 1094-1100.
13. Leavitt RY, Fauci AS, Bloch DA, Michel BA, Hunder GG, et al. (1990) The American College of Rheumatology 1990 criteria for the classification of Wegener's granulomatosis. Arthritis Rheum 33: 1101-1107.
14. Hellmich B, Flossmann O, Gross WL, Bacon P, Cohen-Tervaert JW, et al. (2007) EULAR recommendations for conducting clinical studies and/or clinical trials in systemic vasculitis: focus on anti-neutrophil cytoplasm antibody-associated vasculitis. Ann Rheum Dis 66: 605-617.
15. Warnatz K, (2002) Severe deficiency of switched memory B cells (CD27+IgM-IgD-) in subgroups of patients with common variable immunodeficiency: a new approach to classify a heterogeneous disease. Blood 99: 1544-1551.
16. Wernette CM, Frasch CE, Madore D, Carlone G, Goldblatt D, et al. (2003) Enzyme-linked immunosorbent assay for quantitation of human antibodies to pneumococcal polysaccharides. Clin Diagn Lab Immunol 10: 514-519.
17. Bonilla FA, Bernstein IL, Khan DA, Ballas ZK, Chinen J, et al. (2005) Practice parameter for the diagnosis and management of primary immunodeficiency. Ann Allergy Asthma Immunol 94: S1-63.
18. Keogh KA, Wylam ME, Stone JH, Specks U, (2005) Induction of remission by B lymphocyte depletion in eleven patients with refractory antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum 52: 262-268.
19. Pepper RJ, Fabre MA, Pavesio C, Gaskin G, Jones RB, et al. (2008) Rituximab is effective in the treatment of refractory Churg-Strauss syndrome and is associated with diminished T-cell interleukin-5 production. Rheumatology (Oxford) 47: 1104-1105.
20. Popa C, Leandro MJ, Cambridge G, Edwards JCW, (2007) Repeated B lymphocyte depletion with rituximab in rheumatoid arthritis over 7 yrs. Rheumatology (Oxford) 46: 626-630.
21. van Vollenhoven RF, Emery P, Bingham CO, Keystone EC, Fleischmann R, et al. (2010) Longterm Safety of Patients Receiving Rituximab in Rheumatoid Arthritis Clinical Trials. The Journal of Rheumatology 37: 558-567.
22. Mansfield N, Hamour S, Habib AM, Tarzi R, Levy J, et al. (2011) Prolonged disease-free remission following rituximab and low-dose cyclophosphamide therapy for renal ANCA-associated vasculitis. Nephrology Dialysis Transplantation 26: 3280-3286.
23. Keogh KA, Ytterberg SR, Fervenza FC, Carlson KA, Schroeder DR, et al. (2006) Rituximab for refractory Wegener's granulomatosis: report of a prospective, open-label pilot trial. American journal of respiratory and critical care medicine 173: 180-187.
24. Rees F, Yazdani R, Lanyon P, (2011) Long-term follow-up of different refractory systemic vasculitides treated with rituximab. Clin Rheumatol 30: 1241-1245.
25. Holle JU, Dubrau C, Herlyn K, Heller M, Ambrosch P, et al. (2012) Rituximab for refractory granulomatosis with polyangiitis (Wegener's granulomatosis): comparison of efficacy in granulomatous versus vasculitic manifestations. Ann Rheum Dis 71: 327-333.
26. Jones RB, Ferraro AJ, Chaudhry AN, Brogan P, Salama AD, et al. (2009) A multicenter survey of rituximab therapy for refractory antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum 60: 2156-2168.
27. Irie E, Shirota Y, Suzuki C, Tajima Y, Ishizawa K, et al. (2010) Severe hypogammaglobulinemia persisting for 6 years after treatment with rituximab combined chemotherapy due to arrest of B lymphocyte differentiation together with alteration of T lymphocyte homeostasis. Int J Hematol 91: 501-508.
28. Walker AR, Kleiner A, Rich L, Conners C, Fisher RI, et al. (2008) Profound Hypogammaglobulinemia 7 Years after Treatment for Indolent Lymphoma. Cancer Invest 26: 431-433.
29. Abdulahad WH, Meijer JM, Kroese FGM, Meiners PM, Vissink A, et al. (2011) B cell reconstitution and T helper cell balance after rituximab treatment of active primary Sjögren's syndrome: A double-blind, placebo-controlled study. Arthritis Rheum 63: 1116-1123.
30. Roll P, Palanichamy A, Kneitz C, Dorner T, Tony H-P, (2006) Regeneration of B cell subsets after transient B cell depletion using anti-CD20 antibodies in rheumatoid arthritis. Arthritis Rheum 54: 2377-2386.